Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome.
Understanding of the complex pathways involved in lung injury pathogenesis, resolution …

Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers,
does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human …

Purpose: While various studies have highlighted the prognostic significance of pathologic
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …

Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely
variable clinical outcomes and responses to conventional chemotherapy. We discovered …

Obesity and associated chronic inflammation were shown to facilitate breast cancer (BC)
growth and metastasis. Leptin, adiponectin, estrogen, and several pro-inflammatory …

Importance Pathologic complete response (pCR) is a known prognostic biomarker for long-
term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists …

Background The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …

Improvements in outcomes for patients with resectable lung cancers have plateaued.
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …

Triple-negative breast cancer (TNBC), characterized by the absence or low expression of
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Importance The expense and lengthy follow-up periods for randomized clinical trials (RCTs)
of adjuvant systemic therapy in breast cancer make them impractical and even impossible to …